Biosimilars, Year One: FDA Estimates 2 Applications, 1,720 Hours Of Work
The agency’s expectation is that there will be a limited number of biosimilar applications, but the applicants will need as much time as traditional BLA sponsors to prepare their submissions.
You may also be interested in...
FDA’s Denise Esposito says that in many cases the agency will require biosimilar sponsors to conduct head-to-head comparison studies with the reference product.
Emergence of the inter partes review process dramatically changed the patent dispute arena. The decade also brought biosimilar litigation, generic price-fixing complaints, opioid lawsuits and new government investigations and antitrust actions.
A look back over FDA actions during the past 10 years shows the evolution of its policies on opioids, preemption, off-label promotion and use of real-world evidence.